Table 1_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. …”

Table 3_Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.doc by Xianghua Quan (21404606)

“…However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. …”

Table 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Data Sheet 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.pdf by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 2_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 3_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Image 4_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”

Data Sheet 2_Profile and risk factors of blood donors who experienced adverse reactions: a cross-sectional study on donor hemovigilance data reported to the national network from 2... by Junhong Yang (7807046)

“…Demographic information and data on adverse donor reactions (ADRs) among blood donors were collected from 85 Blood Services. …”

Image 2_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”

Image 5_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”

Image 1_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”

Image 3_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”

Data Sheet 1_Profile and risk factors of blood donors who experienced adverse reactions: a cross-sectional study on donor hemovigilance data reported to the national network from 2... by Junhong Yang (7807046)

“…Demographic information and data on adverse donor reactions (ADRs) among blood donors were collected from 85 Blood Services. …”

Data Sheet 1_Comparison between 75-g and 100-g oral glucose tolerance tests using international association of diabetes and pregnancy study group one-step diagnostic threshold to d... by Li-Li Zhou (1710085)

“…Both groups exhibited similar trends, no significant differences in the risks of adverse outcomes (expressed as ORs) were observed between the 75g and 100g OGTT groups (all p > 0.05).…”

Data Sheet 1_Prevalence trends, population characteristics and treatment outcomes of tuberculosis combined with diabetes in Southwest China: a register-based retrospective study.do... by Deliang Kong (382201)

“…Older age, retreatment, referral, and multiple positive aetiological results were risk factors for adverse treatment outcomes among PTB-DM patients.</p>Conclusion<p>The study presents the true prevalence of PTB-DM comorbidity in the general population of Southwest China, revealing a significant upward trend in its prevalence and a higher risk of adverse outcomes among PTB-DM patients. …”

Table 1_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.xlsx by Yujuan Wu (2249857)

“…</p>Results<p>ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. …”

Table 2_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.docx by Yujuan Wu (2249857)

“…</p>Results<p>ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. …”

Image 1_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…</p>Results<p>ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. …”

Image 2_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…</p>Results<p>ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. …”

Image 3_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…</p>Results<p>ScRNA-seq data revealed decreased CD8+ T and B cell proportions in the CVAEs group, while NK cell proportions increased. …”